Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial

Lam, 2005, Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy, J Urol, 173, 1853, 10.1097/01.ju.0000165693.68449.c3 Crispen, 2008, Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers, Cancer, 113, 450, 10.1002/cncr.23566 Choueiri, 2021, Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma, N Engl J Med, 385, 683, 10.1056/NEJMoa2106391 Ljungberg, 2022, European Association of Urology guidelines on renal cell carcinoma: the 2022 update, Eur Urol, 82, 399, 10.1016/j.eururo.2022.03.006 Motzer, 2015, Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial, J Clin Oncol, 33, 1430, 10.1200/JCO.2014.59.0703 Motzer, 2018, Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma, N Engl J Med, 378, 1277, 10.1056/NEJMoa1712126 Rini, 2019, Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1116, 10.1056/NEJMoa1816714 Motzer, 2019, Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 380, 1103, 10.1056/NEJMoa1816047 Choueiri, 2021, Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma, N Engl J Med, 384, 829, 10.1056/NEJMoa2026982 Gravis, 2016, Effect of glandular metastases on overall survival of patients with metastatic clear cell renal cell carcinoma in the antiangiogenic therapy era, Urol Oncol, 34, 167.e17, 10.1016/j.urolonc.2015.10.015 Grassi, 2016, Outcome of patients with multiple glandular metastases from renal cell carcinoma treated with targeted agents, Ann Oncol, 27, iv34, 10.1093/annonc/mdw334.16 Albiges, 2019, Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): final analysis from the NIVOREN GETUG AFU 26 study, J Clin Oncol, 37, 542, 10.1200/JCO.2019.37.7_suppl.542 Peters, 2013, Incidence of synchronous and metachronous adrenal metastases following tumor nephrectomy in renal cell cancer patients: a retrospective bi-center analysis, Springerplus, 2, 293, 10.1186/2193-1801-2-293 Tanis, 2009, Systematic review of pancreatic surgery for metastatic renal cell carcinoma, Br J Surg, 96, 579, 10.1002/bjs.6606 Principe, 2021, Glandular metastases from renal cell carcinoma show poor clinical responses to immune checkpoint inhibition but durable responses to angiogenesis inhibitors, BMJ Case Rep, 14, e243259, 10.1136/bcr-2021-243259 Antonelli, 2006, Surgical treatment of adrenal metastasis from renal cell carcinoma: a single-centre experience of 45 patients, BJU Int, 97, 505, 10.1111/j.1464-410X.2006.05934.x Lau, 2003, Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review, BJU Int, 91, 775, 10.1046/j.1464-410X.2003.04237.x Motzer, 2020, Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade, Cancer Cell, 38, 803, 10.1016/j.ccell.2020.10.011 Becht, 2015, Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC), OncoImmunology, 4, e1049804, 10.1080/2162402X.2015.1049804 Beuselinck, 2015, Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting, Clin Cancer Res, 21, 1329, 10.1158/1078-0432.CCR-14-1128 Vano, 2022, Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial, Lancet Oncol, 23, 612, 10.1016/S1470-2045(22)00128-0 Roussel, 2021, Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications, Acta Oncol, 60, 1499, 10.1080/0284186X.2021.1962971